Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years (or legal age when higher)~* Chronic AD, that has been present for at least 2 years before the visit~* Eczema Area and Severity Index (EASI) score ≥12~* Investigator Global Assessment (IGA) score ≥ 3~* AD involvement ≥ 10% of Body Surface Area (BSA)~* Severe pruritus on at least 3 of the last 7 days before the visit~* Documented recent history (within 6 months before the visit) of inadequate response to topical medications~* Female subjects must fulfill one of the criteria below:~  * Female subjects of non-childbearing potential~ * Female subjects of childbearing potential who agree to a true abstinence or to use an effective or highly effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration~Exclusion Criteria:~* Body weight \< 45 kg~* subjects with a medical history of asthma requiring hospitalization in the last 12 months before screening visit and/or whose asthma has not been well-controlled during the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) \<80% of the predicted value~* Cutaneous bacterial or viral infection within 1 week before the screening visit or during the run-in period~* Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit or during the run-in period~* History of intolerance to low or mid potency TCS or for whom TCS is not advisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Nemolizumab (low dose)
- Group 2 (Type: EXPERIMENTAL): Nemolizumab (medium dose)
- Group 3 (Type: EXPERIMENTAL): Nemolizumab (high dose)
- Group 4 (Type: PLACEBO_COMPARATOR): Nemolizumab placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).